Search

EHA Research Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Chairs and members

Chair (2024–2027)
Elizabeth Macintyre, Hôpital Necker-Enfants Malades et Université Paris, France
Vice-Chair (2024–2027)
Margarita Guenova, National Specialised Hospital for Active Treatment of Haematological Diseases, Belgium
Steering Committee (2024–2027)
Monika Brüggemann, University Hospital Kiel, Germany (ESHLO)
Francesco Buccisano, Tor Vergata University of Rome, Italy (SWG on Diagnosis…

Highlights from the SWG

The SWG organized a EHA scientific workshop entitled: “Shaping the future of MSC Therapy” in Amsterdam from November 23-25, 2017.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.